Avenue Therapeutics Inc (ATXI)
2.51
+0.16
(+7.04%)
USD |
NASDAQ |
Sep 27, 16:00
2.51
0.00 (0.00%)
After-Hours: 20:00
Avenue Therapeutics Research and Development Expense (Annual): 10.36M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 10.36M |
| December 31, 2022 | 2.698M |
| December 31, 2021 | 1.254M |
| December 31, 2020 | 2.866M |
| Date | Value |
|---|---|
| December 31, 2019 | 23.19M |
| December 31, 2018 | 17.70M |
| December 31, 2017 | 7.801M |
| December 31, 2016 | 1.38M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
1.254M
Minimum
2021
23.19M
Maximum
2019
8.075M
Average
2.866M
Median
2020
Research and Development Expense (Annual) Benchmarks
| Fortress Biotech Inc | 106.07M |
| Checkpoint Therapeutics Inc | 43.57M |
| Journey Medical Corp | 7.541M |
| NovaBay Pharmaceuticals Inc | 0.068M |
| Palatin Technologies Inc | 22.63M |